Funding for this research was provided by:
Bundesministerium für Bildung und Forschung (13N 13341)
Received: 7 June 2021
Accepted: 9 August 2021
First Online: 21 August 2021
: All experiments in animals were conducted in compliance with the German animal protection law (permission number 35-91185.81/G-158/15). Imaging of the patient was performed under the conditions of the updated declaration of Helsinki, §37 (unproven interventions in clinical practice) and in accordance to the German Pharmaceuticals Law §13 (2b) for medical reasons. The data were analyzed retrospectively with approval of the local ethics committee (No. S016/2018). The datasets generated, used and analyzed during this study are included in this published article and, with additional datasets, in the supplementary information file. Additional data can be requested from the corresponding author.
: Patent application (EP 18155420.5) for quinoline based FAP targeting agents for imaging and therapy in nuclear medicine (UH, TL, FG, CK and WM).